Ed Kaye

Credit Suisse analyst Alethia Young reiterated an Outperform rating on Sarepta Therapeutics Inc (NASDAQ: SRPT) with a $64 price target, following the announcement of a new CEO and ahead of several other catalysts. Sarepta announced Wednesday that Doug Ingram has been appointed CEO. He will...

Sarepta Therapeutics Inc (NASDAQ: SRPT) shares are up more than 6.5 percent Friday after the company reported first-quarter net revenue from EXONDYS 51 of $16.3 million and guided for $95 million in revenue for the full year, up from previous guidance of $80 million. In addition to the revenue beat...